News blog


  • BY: Andrew Hore |
  • POSTED: 01/11/2010 |

Skin treatments developer Syntopix has signed a second agreement with Sinclair Pharma.

This time Sinclair is paying a development contract fee to develop a combination of Sinclair’s Delmopinol and some potentially synergistic anti-microbial compounds in to proof of concept development formulations. Syntopix will receive royalties on any commercialised treatments.

The first agreement was announced in April and involved identifying anti-microbial compounds to augment Decapinol.

At 62p a share, Syntopix is valued at 6.64m. 

© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds